Lactoferrin in enteric formulation is able to resist the enzymatic activity of stomach pepsin agents and, at 10 times higher concentration in the circulation compared to lactoferrin, could be considered an important neutraceutical which is potentially effective for prophylaxis and therapeutic administration in COVID-19 subjects [238,239,240]. This evidence concerns the gene LTF and COVID-19.